CLIA deadline extension
This article was originally published in The Gray Sheet
Executive SummaryHealth Care Financing Administration is aiming to publish in the next few weeks a notice in the Federal Register extending the Sept. 1, 1994 deadline by which all in vitro diagnostic test labeling was supposed to conform to the quality control provisions of the Clinical Laboratories Improvement Amendments of 1988 ("The Gray Sheet" Jan. 10, I&W-6). An extension of two to four years is expected. Under current regs, laboratories can not after Sept. 1 use IVD QC instructions as a substitute for CLIA QC rules unless the labeling is cleared by FDA. HCFA says it will not enforce the provision if the extension is not published before the deadline
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.